CMV Infection After Transplant: Who’s at Risk and How to Manage?

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

CMV Infection After Transplant: Who’s at Risk and How to Manage?



ReachMD Healthcare Image

Find out which of our patients are at risk for cytomegalovirus infection after HCT and SOT and how we can manage them.

  • Sponsored by

  • Overview

    Unfortunately, cytomegalovirus (CMV) infection occurs in many patients after hematopoietic-cell transplantation (HCT) and solid-organ transplant (SOT). In fact, it occurs in as high as 75 percent of SOT recipients and up to 30 percent of HCT recipients.1 Given this prevalence, effectively managing CMV is essential to help improve transplant outcomes.2-4 That’s why Dr. Jennifer Caudle speaks with Dr. Cedric Spak about the impacts and risk factors associated with CMV infection along with key management strategies. Dr. Spak is a Physician Partner at Texas Centers for Infectious Disease Associates.

  • References:

    1. Azevedo LS, Pierrotti LC, Abdala E, et al. Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo). 2015;70(7):515-523. doi:10.6061/clinics/2015(07)09
    2. Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119-e127. doi:10.1016/S2352-3026(15)00289-6
    3. Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900-931. doi:10.1097/TP.0000000000002191
    4. Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a Phase 3 randomized clinical trial. Clin Infect Dis. 2022;75(4):690-701. doi:10.1093/cid/ciab988

    ©2024 Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Avenue, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda Pharmaceutical Company Limited.
    US-NON-10706v1.0 02/24

Schedule17 May 2024